Levi & Korsinsky Reminds Supernus Pharmaceuticals, Inc. Investors of the Ongoing Investigation into Potential Violations of Securities Laws - SUPN
Portfolio Pulse from
Levi & Korsinsky has initiated an investigation into Supernus Pharmaceuticals, Inc. for potential securities law violations after the company's Phase 2b study of SPN-820 failed to meet its primary endpoint.
March 06, 2025 | 12:45 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Supernus Pharmaceuticals is under investigation for potential securities law violations following the failure of its SPN-820 study to meet primary endpoints.
The investigation into potential securities law violations and the failure of the SPN-820 study are likely to negatively impact investor confidence and the stock price of Supernus Pharmaceuticals in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100